Delphine Gamondes MD, Presenter: Nothing to Disclose

Loïc Boussel, Abstract Co-Author: Nothing to Disclose

Mickael Ribagnac, Abstract Co-Author: Nothing to Disclose

Philippe Charles Douek MD, PhD, Abstract Co-Author: Nothing to Disclose

Didier Revel, Abstract Co-Author: Nothing to Disclose

In hereditary hemorrhagic telangiectasia (HHT), post-embolotherapy recurrence of Pulmonary Arteriovenous Malformations (PAVMs) patency is often difficult to assess with CT. We evaluated whether the measurement of the diameter of the efferent vein could be an accurate predictor for PAVMs patency.

We studied 89 consecutive patients presenting with HHT and PAVMs who underwent at least two sessions of embolotherapy. The CTs performed systematically within 7 days prior to the last sessions were considered in this study. The diameter of the efferent vein of all the previously treated PAVMs were blindly measured and compared to the per- embolotherapy findings in term of PAVM patency. A ROC analysis was performed to determine the optimal predicting vein diameter.

50 over 176 analyzed PAVMs were recurrent. Mean efferent vein diameter was respectively 4.3+/-1.5 and 1.6+/-0.8 mm for the patent and non-patent PAVMs. Optimal cut-off diameter from the ROC analysis was 3 mm (sensitivity=93.5%; specificity=91.2%). A sensitivity of 100% was reached for a diameter larger than 2 mm.

Diameter of the efferent vein may be proposed as a marker for detection of PAVMs patency recurrence.

Measurement of the diameter of the efferent vein predicts PAVMs patency recurrence.

Gamondes, D, Boussel, L, Ribagnac, M, Douek, P, Revel, D, Diameter of the Efferent Vein: An Accurate Marker for Detection of Pulmonary Arteriovenous Malformations Patency Recurrence after Embolotherapy.  Radiological Society of North America 2010 Scientific Assembly and Annual Meeting, November 28 - December 3, 2010 ,Chicago IL. http://archive.rsna.org/2010/9010853.html